Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.

Gil T, Aoun F, Cabri P, Perrot V, van Velthoven R

Therapeutic advances in urology21 Jun 2017Cited by 5 (Europe PMC)

PMID28747996PMCIDPMC5510771DOI10.1177/1756287217712379PepBankPUB-28747996

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In men with advanced prostate cancer, triptorelin treatment was associated with fewer moderate or severe urinary symptoms at 24 and 48 weeks.
In plain wordsIn men with advanced prostate cancer, triptorelin treatment was linked to fewer moderate or severe urinary symptoms than at baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseModerate or severe lower urinary tract symptoms
Study
n = 1,851
Comparator
Baseline
Analysis
Primary
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated · 48 weeksAs given in this study (human).
Measurements
Moderate or severe symptom proportion
75.9%
week 24
Moderate or severe symptom proportion
67.2%
week 48
Source sentences
Summary
The proportion of patients with moderate or severe LUTSs was reduced to 67.2% from baseline at week 48, following a reduction to 75.9% at week 24: the overall time effect was significant (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A grouped analysis of national observational, non-interventional studies initiated in clinical practice was performed to assess the effectiveness of triptorelin in reducing moderate or severe LUTSs, measured using the International Prostate Symptom Score (IPSS) in men with advanced or metastatic PCa.
Summary · context
A total of 2701 patients were recruited; 1851 patients with moderate or severe LUTSs at baseline (IPSS > 7), received triptorelin and had follow-up IPSS (efficacy population).
Report a problemFND-2874799601
02HumanObservational studyEfficacy outcome
In men with advanced prostate cancer, urinary symptom quality-of-life scores improved during triptorelin treatment compared with baseline.
In plain wordsIn men with advanced prostate cancer, triptorelin treatment was linked to better urinary quality-of-life scores than at baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseQuality of life due to urinary symptoms
Study
n = 1,851
Comparator
Baseline
Analysis
Secondary
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated · 48 weeksAs given in this study (human).
Measurements
Mean quality-of-life score
3.7 score
baseline
Adjusted mean quality-of-life score
2.5 score
week 24
Adjusted mean quality-of-life score
2.1 score
week 48
Source sentences
Summary
QoL due to urinary symptoms significantly improved from a mean score of 3.7 at baseline, to adjusted means of 2.5 and 2.1, at weeks 24 and 48, respectively (p versus baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
A grouped analysis of national observational, non-interventional studies initiated in clinical practice was performed to assess the effectiveness of triptorelin in reducing moderate or severe LUTSs, measured using the International Prostate Symptom Score (IPSS) in men with advanced or metastatic PCa.
Summary · context
A total of 2701 patients were recruited; 1851 patients with moderate or severe LUTSs at baseline (IPSS > 7), received triptorelin and had follow-up IPSS (efficacy population).
Report a problemFND-2874799602
03HumanObservational studyEfficacy outcome
In men with advanced prostate cancer, mean PSA decreased during triptorelin treatment compared with baseline.
In plain wordsIn men with advanced prostate cancer, triptorelin treatment was linked to lower PSA than at baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseProstate-specific antigen
Study
n = 1,851
Comparator
Baseline
Analysis
Secondary
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
Dose not stated · 48 weeksAs given in this study (human).
Measurements
Mean PSA
158.8 ng/ml
baseline
Mean PSA
11.5 ng/ml
week 24
Mean PSA
16 ng/ml
week 48
Source sentences
Summary
Mean PSA levels were reduced from 158.8 ng/ml at baseline to 11.5 and 16.0 ng/ml at weeks 24 and 48, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A grouped analysis of national observational, non-interventional studies initiated in clinical practice was performed to assess the effectiveness of triptorelin in reducing moderate or severe LUTSs, measured using the International Prostate Symptom Score (IPSS) in men with advanced or metastatic PCa.
Summary · context
A total of 2701 patients were recruited; 1851 patients with moderate or severe LUTSs at baseline (IPSS > 7), received triptorelin and had follow-up IPSS (efficacy population).
Report a problemFND-2874799603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.